ARGENX SE
No enriched coverage for $ARGX in the last 7 days.
No SEC Form 4 filings for $ARGX in the last 30 days.
See all $ARGX insider activity →Argenx reported 18 consecutive quarters of revenue growth, with Q2 2026 sales up 60% year-over-year. Its therapies Vyvgart and Vyvgart Hytrulo are driving growth, with expanding operating margins. The company expects further growth from new indications and pipeline developments. Analysts rate it a buy, with a 14% upside target.
argenx (ARGX) reported positive Phase 3 trial results for VYVGART Hytrulo in treating autoimmune myositis. Shares have surged, with a 1-year return of 50.58%. Analysts debate valuation, with some calling it 32.2% overvalued at €907.40, while others see a 52.2% discount. Investors should watch for clinical setbacks and pricing pressures.
UBS upgraded SolarEdge (SEDG) to Buy with a $42 target, citing FCC benefits. Wolfe upgraded DT Midstream (DTM) to Outperform with a $145 target. Piper upgraded Neogen (NEOG) to Overweight with a $14 target. UBS upgraded Argenx (ARGX) to Buy with a $1,400 target. National Bank upgraded Scotiabank (BNS) to Outperform with a C$142 target. JPMorgan and BofA downgraded Intuit (INTU) to Neutral with a $331 target. Truist downgraded Dick's Sporting (DKS) and Nike (NKE). Wells downgraded GoDaddy (GDDY).
Recent ARGX coverage spans financial news, technology and market movers.
Positive pivotal data could expand the Vyvgart franchise and drive near‑term share upside.
The trial success is likely to drive significant upside for argenx as the drug moves toward potential approval.
Buy rating may drive price higher.
Positive analyst upgrade and higher target suggest upside potential.
Analyst upgrade may support short‑term price appreciation.
AlphAI scores every news story that mentions ARGX with an AI model for sentiment and relevance, and aggregates insider trades from ARGENX SE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Argenx reported 18 consecutive quarters of revenue growth, with Q2 2026 sales up 60% year-over-year. Its therapies Vyvgart and Vyvgart Hytrulo are driving growth, with expanding operating margins. The company expects further growth from new indications and pipeline developments. Analysts rate it a buy, with a 14% upside target.
2 min readargenx (ARGX) reported positive Phase 3 trial results for VYVGART Hytrulo in treating autoimmune myositis. Shares have surged, with a 1-year return of 50.58%. Analysts debate valuation, with some calling it 32.2% overvalued at €907.40, while others see a 52.2% discount. Investors should watch for clinical setbacks and pricing pressures.
2 min readUBS upgraded SolarEdge (SEDG) to Buy with a $42 target, citing FCC benefits. Wolfe upgraded DT Midstream (DTM) to Outperform with a $145 target. Piper upgraded Neogen (NEOG) to Overweight with a $14 target. UBS upgraded Argenx (ARGX) to Buy with a $1,400 target. National Bank upgraded Scotiabank (BNS) to Outperform with a C$142 target. JPMorgan and BofA downgraded Intuit (INTU) to Neutral with a $331 target. Truist downgraded Dick's Sporting (DKS) and Nike (NKE). Wells downgraded GoDaddy (GDDY).
2 min readUBS upgraded argenx SE (ARGX) to Buy with a $1,400 price target, citing positive trial results for Vyvgart. ARGX's stock is trading at $1,048.84, 29.0% below its GF Value™ of $1,478.00. The company has a GF Score™ of 78, strong financial health, and a growing pipeline. Institutional interest remains high, with 8 gurus holding shares.
2 min readWells Fargo maintained an Overweight rating on argenx (ARGX) and raised its price target from $1350 to $1415, a 4.81% increase. The company's stock is currently trading at $1019.50, with a GF Value™ of $1478.00, indicating a 31.0% undervaluation. argenx has a GF Score™ of 78/100, reflecting strong financial strength and growth potential. The company focuses on developing antibody-based therapies for rare autoimmune diseases.
2 min readargenx (ARGX) reported positive Phase III results for efgartigimod in treating autoimmune myositis, with a 15.4-point improvement in TIS over placebo. The company's shares rose 8% to 789 euros.
1 min readUBS upgraded Argenx (ARGX) to Buy with a $1,400 price target, citing Vyvgart's potential for $18B peak sales and a strong pipeline. The stock rose 2.8% in Brussels. Analyst Xian Deng highlighted better-than-expected Phase 3 data and underappreciated pipeline assets, including empasiprubart and a recent $2B acquisition.
2 min readWall Street analysts issued upgrades, downgrades, and initiations for several companies. Upgrades include argenx (ARGX) to Buy at UBS, DT Midstream (DTM) to Outperform at Wolfe Research, and SolarEdge (SEDG) to Buy at UBS. Downgrades include Dick's Sporting Goods (DKS) to Hold at Truist, EPAM Systems (EPAM) to Neutral at JPMorgan, and Intuit (INTU) to Neutral at Bank of America. Initiations include Atlassian (TEAM) with Outperform at RBC, JFrog (FROG) with Outperform at RBC, and Lattice Semicond
4 min readArgenx (ARGX) reported positive Phase 3 trial results for Vyvgart Hytrulo in treating autoimmune myositis, meeting primary endpoints for IMNM but not DM. The stock surged over 20%. Argenx has multiple late-stage trials and acquisitions in progress, with analysts largely bullish but price targets reflecting modest upside.
2 min readUBS upgraded its recommendation for Argenx SE to Buy. The rating is based on a weighted average of several factors, including valuation, EPS revisions, and visibility. The company's shares traded at 897.60 EUR, up 2.09%, on Euronext Bruxelles.
1 min read
